Skip to content
Screener

Bausch + Lomb BLCO Total costs & expenses

Total costs & expenses at other companies

LENSAR, Inc. logo
LENSAR, Inc.LNSR
$4.14M-67.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$104.13M+39.5%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$193.82M+55.2%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$3.47B+75.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3B+15.5%
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.84B+17.0%
Enterprise value$10.54B+8.9%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development11496215182
Amortization of intangible assets5767114134
Other expense, net25225144
1,3111,2892,5222,509
Operating income (loss)83(11)116(94)
Interest income4386
Interest expense(93)(128)(190)(222)
Loss on extinguishment of debt(9)(1)(9)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's total costs & expenses?
Bausch + Lomb (BLCO) reported total costs & expenses of $1.31B in Q2 2026.
How has Bausch + Lomb's total costs & expenses changed year-over-year?
Bausch + Lomb's total costs & expenses increased by 1.7% year-over-year, from $1.29B to $1.31B.
What is the long-term trend for Bausch + Lomb's total costs & expenses?
Over 4 years (2021 to 2025), Bausch + Lomb's total costs & expenses has grown at a 9.8% compound annual growth rate (CAGR), from $3.44B to $4.99B.
What does total costs & expenses mean?
This metric aggregates all operating costs incurred by the company to generate revenue, including cost of goods sold, research and development, and selling, general, and administrative expenses. It serves as a comprehensive measure of the total resources consumed by the business to maintain its operations and market position. Analyzing this figure helps investors evaluate the company's overall cost structure and operational discipline relative to its revenue generation.

Ask your AI about Bausch + Lomb's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude